FI960979A0 - Menetelmä humorralisen immuunivasteen suppressoimiseksi - Google Patents
Menetelmä humorralisen immuunivasteen suppressoimiseksiInfo
- Publication number
- FI960979A0 FI960979A0 FI960979A FI960979A FI960979A0 FI 960979 A0 FI960979 A0 FI 960979A0 FI 960979 A FI960979 A FI 960979A FI 960979 A FI960979 A FI 960979A FI 960979 A0 FI960979 A0 FI 960979A0
- Authority
- FI
- Finland
- Prior art keywords
- humoral immune
- suppression
- immune response
- procedure
- antagonist
- Prior art date
Links
- 230000028996 humoral immune response Effects 0.000 title abstract 3
- 230000001629 suppression Effects 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 abstract 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 210000001541 thymus gland Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11599093A | 1993-09-02 | 1993-09-02 | |
| US11599093 | 1993-09-02 | ||
| US23292994 | 1994-04-25 | ||
| US08/232,929 US5869049A (en) | 1993-09-02 | 1994-04-25 | Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists |
| PCT/US1994/009872 WO1995006480A1 (en) | 1993-09-02 | 1994-09-02 | Methods of prolonged suppression of humoral immunity |
| US9409872 | 1994-09-02 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI960979A0 true FI960979A0 (fi) | 1996-03-01 |
| FI960979A FI960979A (fi) | 1996-04-30 |
| FI106927B FI106927B (fi) | 2001-05-15 |
Family
ID=26813793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI960979A FI106927B (fi) | 1993-09-02 | 1996-03-01 | Menetelmä sen määrittämiseksi, onko antigeeni TD-antigeeni vai TI-2-antigeeni |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0742721B1 (fi) |
| JP (1) | JP2840131B2 (fi) |
| CN (1) | CN1137726C (fi) |
| AT (1) | ATE179616T1 (fi) |
| AU (3) | AU7643094A (fi) |
| DE (1) | DE69418349T2 (fi) |
| DK (1) | DK0742721T3 (fi) |
| ES (1) | ES2134954T3 (fi) |
| FI (1) | FI106927B (fi) |
| GR (1) | GR3030762T3 (fi) |
| IL (1) | IL110852A (fi) |
| NO (1) | NO321037B1 (fi) |
| NZ (1) | NZ273208A (fi) |
| WO (1) | WO1995006480A1 (fi) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7070777B1 (en) | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| ATE356634T1 (de) * | 1997-01-10 | 2007-04-15 | Biogen Idec Inc | Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln |
| EP1101495A4 (en) * | 1999-06-01 | 2003-05-07 | Eisai Co Ltd | PREVENTIVE AGENTS AGAINST IDIOPATHIC THROMOBOCYTOPENIC PURPURA |
| WO2001079555A2 (en) | 2000-04-14 | 2001-10-25 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
| AU6158501A (en) | 2000-05-12 | 2001-11-26 | Beth Israel Hospital | Compositions and methods for achieving immune suppression |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| WO2013013708A1 (en) | 2011-07-26 | 2013-01-31 | Fundació Institut D'investigació Biomèdica De Bellvitge | Treatment of acute rejection in renal transplant |
| EP3094652B1 (en) | 2014-01-13 | 2021-09-29 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
| US10669343B2 (en) | 2015-08-05 | 2020-06-02 | Janssen Biotech, Inc. | Anti-CD154 antibodies and methods of using them |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69233051T2 (de) * | 1991-10-25 | 2004-03-11 | Immunex Corp., Seattle | Antikörper gegen CD40-L |
| IL104684A0 (en) * | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
| AU655349B2 (en) * | 1992-02-17 | 1994-12-15 | Kenji Nakamura | An antibacterial porous inorganic capsule and a process for producing the same |
-
1994
- 1994-09-02 WO PCT/US1994/009872 patent/WO1995006480A1/en active IP Right Grant
- 1994-09-02 CN CNB941940055A patent/CN1137726C/zh not_active Expired - Fee Related
- 1994-09-02 NZ NZ273208A patent/NZ273208A/xx not_active IP Right Cessation
- 1994-09-02 AT AT94926660T patent/ATE179616T1/de not_active IP Right Cessation
- 1994-09-02 JP JP7508266A patent/JP2840131B2/ja not_active Expired - Fee Related
- 1994-09-02 AU AU76430/94A patent/AU7643094A/en not_active Abandoned
- 1994-09-02 IL IL11085294A patent/IL110852A/xx not_active IP Right Cessation
- 1994-09-02 ES ES94926660T patent/ES2134954T3/es not_active Expired - Lifetime
- 1994-09-02 DE DE69418349T patent/DE69418349T2/de not_active Expired - Fee Related
- 1994-09-02 EP EP94926660A patent/EP0742721B1/en not_active Revoked
- 1994-09-02 DK DK94926660T patent/DK0742721T3/da active
-
1996
- 1996-03-01 NO NO19960863A patent/NO321037B1/no not_active IP Right Cessation
- 1996-03-01 FI FI960979A patent/FI106927B/fi active
-
1999
- 1999-01-29 AU AU14220/99A patent/AU734853B2/en not_active Ceased
- 1999-07-14 GR GR990401847T patent/GR3030762T3/el unknown
-
2004
- 2004-12-16 AU AU2004240180A patent/AU2004240180B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1995006480A1 (en) | 1995-03-09 |
| GR3030762T3 (en) | 1999-11-30 |
| FI960979A (fi) | 1996-04-30 |
| FI106927B (fi) | 2001-05-15 |
| IL110852A0 (en) | 1994-11-28 |
| DE69418349D1 (de) | 1999-06-10 |
| NO960863L (no) | 1996-04-30 |
| JPH09502184A (ja) | 1997-03-04 |
| AU2004240180B2 (en) | 2007-08-09 |
| ES2134954T3 (es) | 1999-10-16 |
| EP0742721A1 (en) | 1996-11-20 |
| DE69418349T2 (de) | 1999-09-09 |
| AU7643094A (en) | 1995-03-22 |
| AU2004240180A1 (en) | 2005-01-27 |
| DK0742721T3 (da) | 1999-11-01 |
| NZ273208A (en) | 2000-12-22 |
| IL110852A (en) | 1999-05-09 |
| CN1137758A (zh) | 1996-12-11 |
| JP2840131B2 (ja) | 1998-12-24 |
| AU734853B2 (en) | 2001-06-21 |
| AU1422099A (en) | 1999-04-01 |
| EP0742721B1 (en) | 1999-05-06 |
| NO321037B1 (no) | 2006-03-06 |
| ATE179616T1 (de) | 1999-05-15 |
| NO960863D0 (no) | 1996-03-01 |
| CN1137726C (zh) | 2004-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI960979A (fi) | Menetelmä humorralisen immuunivasteen suppressoimiseksi | |
| ATE306939T1 (de) | Mehrstufiger kaskade-erhöhungsimpfstoff | |
| GR3030568T3 (en) | Inducing cytotoxic t lymphocyte responses. | |
| MX9704097A (es) | Induccion de respuestas de linfocitos t citotoxicos. | |
| EP0863913A4 (en) | METHOD FOR RECOVERING THE DENSITY OF ANTIGENS ON ANTIGENT PRESENTING CELLS | |
| OA09880A (en) | Induction of cytotoxic T-Lymphocyte Responses | |
| DK0724432T3 (da) | Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner | |
| ATE295895T1 (de) | Genetischer impfstoff gegen den immunschwäche virus | |
| ATE326231T1 (de) | Mutierendes enterotoxin als nichttoxisches orales adjuvans | |
| CA2143823A1 (en) | Retro-, inverso - and retro-inverso synthetic peptide analogues | |
| MX9405383A (es) | Imidazo(4,5-c) piridin-4-aminas. | |
| PT991403E (pt) | Uso de microparticulas com antigenio adsorvido para estimular respostas imunes | |
| DE122010000015I1 (de) | Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten | |
| CA2121498A1 (en) | Recombitope peptides | |
| DE69837896D1 (de) | Peptide von carcinoembryonischem Antigen (CEA) mit Tachykinin-antagonistischer Aktivität | |
| DK0882132T3 (da) | Et kombineret humant cytomegalovirus-antigen og anvendelse heraf | |
| PT1021196E (pt) | Utilizacao de uma solucao de clorito quimicamente estabilizada para inibir uma resposta imunitaria especifica para antigenio | |
| EP0062574A3 (en) | Virus protein synthesis | |
| OA08782A (en) | Immunologically active polypeptides useful for the preparation of antimalarial vaccines and of diagnostic kits for the detection of antisporozoite antibodies. | |
| IT8368342A0 (it) | Procedimento e dispositivo per lapreparazione di bevande gassate particolarmente per uso in ambiente domestico | |
| WO2001035993A3 (en) | Compositions and methods for stimulating an immune response against infectious agents | |
| AU1796492A (en) | Antigen recognized by antibodies associated with paraneoplastic opsoclonus and methods of use thereof | |
| CA2128247A1 (en) | Vaccines based on streptokinase | |
| DK0929315T3 (da) | Krydsbeskyttende equine herpesviruspræparater, deres fremstilling og anvendelse | |
| IT1217177B (it) | Palmitoil-fruttosio-1,6-difosfato,suo uso terapeutico e relativi metodi di preparazione |